Company intelligence / Profile preview

Shanghai Hanson Biomedical Technology

Lianyungang, Jiangsu, China

Ownership: Private
Employees: ~8700
Development stage: Other

Overview

Hansoh Pharma has moved multiple innovative programs into Phase 3 and beyond, with several drugs already approved in China (including ameile/ aumolertinib, Hansoh Xinfu/ flumatinib, and Fulaimei/ PEG-loxenatide). The company has ADCs at Phase 3 and major partnering and licensing deals (GSK, Merck).

Therapeutic areas: ImmunologyEndocrinologyInfectious DiseasesDermatologyOncologyNeurology
Modalities: Antibody-drug conjugateSmall moleculeMonoclonal antibodyFusion proteinBiologicsiRNAProteinRecombinant protein
Industry: Biotech

Partnerships

GSKMerck (MSD)Regeneron

Beyond the preview

Go deeper on Shanghai Hanson Biomedical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Hanson Biomedical Technology.

Explore the full profile